Sanofi UroXatral Approval For BPH Includes Phase IV QT Study Commitment

23 Jun 2003

• By The Pink Sheet

Sanofi-Synthelabo's UroXatral Phase IV study will examine potential QT prolongation of alfuzosin in combination with a phosphodiesterase inhibitor erectile dysfunction agent following June 12 approval of the drug

Sanofi UroXatral Approval For BPH Includes Phase IV QT Study Commitment

More from Archive

More from Pink Sheet